Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does adjuvant androgen suppression after radiotherapy for prostate cancer improve long-term outcomes?

Nature Clinical Practice Urology volume 2, pages 536–537 (2005)Cite this article

boxed-textPilepich MV et al. (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85–31. Int J Radiat Oncol Biol Phys 61: 1285–1290

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pilepich MV et al. (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61: 1285–1290

    Article  CAS  Google Scholar 

  2. Pilepich MV et al. (1997) Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85-31. J Clin Oncol 15: 1013–1021

    Article  CAS  Google Scholar 

  3. Lawton CA et al. (2001) Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49: 937–946

    Article  CAS  Google Scholar 

  4. Hanks GE et al. (2003) Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group protocol 92-02. J Clin Oncol 21: 3972–3978

    Article  CAS  Google Scholar 

  5. Pilepich MV et al. (2001) Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50: 1243–1252

    Article  CAS  Google Scholar 

  6. Bolla M et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360: 103–106

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Sandra Michelmore, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Radiation Oncology and Head of the Federation of Oncology at the Centre Hospitalier Universitaire de Grenoble, Grenoble, France

    Michel Bolla

Authors
  1. Michel Bolla
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michel Bolla.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bolla, M. Does adjuvant androgen suppression after radiotherapy for prostate cancer improve long-term outcomes?. Nat Rev Urol 2, 536–537 (2005). https://doi.org/10.1038/ncpuro0331

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0331

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing